RVMD Logo

Revolution Medicines, Inc. (RVMD) 

NASDAQ
Market Cap
$9.58B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
698 of 774
Rank in Industry
383 of 432

Largest Insider Buys in Sector

RVMD Stock Price History Chart

RVMD Stock Performance

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the …

Insider Activity of Revolution Medicines, Inc.

Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $0 and sold $24.36M worth of Revolution Medicines, Inc. stock.

On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $20.77M and sold $87.87M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $2.05M was made by Schroeder Thilo (director) on 2023‑03‑10.

List of Insider Buy and Sell Transactions, Revolution Medicines, Inc.

2024-11-15SaleGeneral Counsel
2,554
0.0015%
$55.13$140,811+3.52%
2024-11-13SaleSee Remarks
16,666
0.0099%
$58.65$977,509-3.49%
2024-11-06SaleGeneral Counsel
6,000
0.0037%
$60.00$360,000-0.54%
2024-11-04SaleSee Remarks
50,900
0.0301%
$55.56$2.83M+5.99%
2024-11-01SaleSee Remarks
19,100
0.0114%
$55.02$1.05M+7.28%
2024-10-31Saledirector
5,000
0.003%
$54.14$270,715+9.56%
2024-10-14SaleSee Remarks
16,666
0.0113%
$49.49$824,804+11.97%
2024-10-11SaleSee Remarks
30,000
0.0206%
$50.36$1.51M+9.13%
2024-10-11SaleChief Operating Officer
50,000
0.0344%
$50.34$2.52M+9.13%
2024-10-11SaleChief Financial Officer
10,000
0.0069%
$50.30$502,979+9.13%
2024-10-11SaleGeneral Counsel
6,000
0.0041%
$50.17$301,027+9.13%
2024-10-08Saledirector
5,200
0.0034%
$48.02$249,716+4.48%
2024-10-01SaleSee Remarks
10,000
0.0061%
$44.93$449,322+11.64%
2024-09-16SaleSee Remarks
11,715
0.007%
$44.19$517,631+11.74%
2024-09-16SaleSee Remarks
4,665
0.0028%
$44.19$206,124+11.74%
2024-09-16SaleChief Operating Officer
4,331
0.0026%
$44.19$191,367+11.74%
2024-09-16SaleChief Financial Officer
2,244
0.0013%
$44.19$99,152+11.74%
2024-09-16SaleGeneral Counsel
1,454
0.0009%
$44.19$64,245+11.74%
2024-09-13SaleSee Remarks
16,667
0.0099%
$43.32$722,087+13.58%
2024-08-13SaleSee Remarks
16,667
0.01%
$42.98$716,3890.00%

Insider Historical Profitability

9.41%
Schroeder Thilodirector
1553134
0.9233%
$56.94140+9.37%
Flynn James E10 percent owner
1297589
0.7714%
$56.9410+14.18%
Kim Lorence H.
60500
0.036%
$56.9410+5.12%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$475.62M8.9414.76M+0.84%+$3.96M0.01
Wellington Management Company$474.26M8.9214.71M-1.13%-$5.39M0.08
BlackRock$396.69M7.4612.31M-4.99%-$20.83M0.01
Baker Bros Advisors LP$243.31M4.587.55M+46.63%+$77.37M1.75
Farallon Capital$241.98M4.557.51M+11.45%+$24.85M1.7
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.